Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Blood (2024) 144 (Supplement 1): 3019.

https://doi.org/10.1182/blood-2024-204328

Published: 2024

Journal Articles

Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Fiona Swain, Melinda Burgess, Sarah Kempe, Muhammed B. Sabdia, Andrea S Henden, Joel Wight, Eliza A. Hawkes, Howard Mutsando, Dipti Talaulikar, Lilia Merida de Long, Simone Birch, Penelope Wyche, Zachary Hawula, Rakin Chowdhury, Maher K. Gandhi, Colm Keane

Blood (2024) 144 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2024-199352

Published: 2024

Journal Articles

Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study

Yao Yao, Serif Sungur, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Eliza A. Hawkes, Erica M. Wood, Nada Hamad, Anna M. Johnston, Tasman Armytage

Blood (2024) 144 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2024-202797

Published: 2024

Journal Articles

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, Biyi Shen, Jingjin Li, Claire Hearnden, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan

Blood (2024) 144 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2024-200623

Published: 2024

Journal Articles

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rachel Koldej, Allison Barraclough, Sze Ting Lee, Huw Morgan, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes

Blood (2024) 144 (Supplement 1): 4376.

https://doi.org/10.1182/blood-2024-199854

Published: 2024

Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Blood (2024) 144 (Supplement 1): 4501.

https://doi.org/10.1182/blood-2024-199281

Published: 2024

Journal Articles

Toxicity Outcomes in Phase 1 Lymphoma Trials: Variable Reporting with High Use of Minimising Language in Published Abstracts at International Conferences

Marsali Maclean, Niamh Waters, Charmaine Smith, Darcy Vickers, Dawn Swan, Arina Martynchyk, Denise Lee, Geoffrey Chong, Eliza A. Hawkes

Blood (2024) 144 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2024-198377

Published: 2024

Journal Articles

Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Maciej Tatarczuch, Colm Keane, Christina Brown, Pratyush Giri, Gavin Cull, Masa Lasica, Charles Shuttleworth, Joel Wight, Marjan Tabesh, Belinda E Butcher, Sze Ting Lee, Eliza A. Hawkes, Gareth P. Gregory

Blood (2024) 144 (Supplement 1): 4502.2.

https://doi.org/10.1182/blood-2024-200410

Published: 2024

Journal Articles

Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Luani Barge, Joshua W.D. Tobin, Niamh Waters, Ross Salvaris, Sam Lai, Tessa Potezny, Helen Cashman, Caitlyn Nguyen-Ngo, Denise Lee, Costas K. Yannakou, Nada Hamad, Constantine S. Tam, Abir Bhattacharyya, Chan Y. Cheah, Kirk Morris, Eliza A. Hawkes, Greg Hapgood

Blood (2024) 144 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2024-203146

Published: 2024

Journal Articles

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

Rakin Chowdhury, Kate Manos, Melinda Burgess, Geoffrey Chong, Sze-Ting Lee, Zachary Hawula, Nella Tuczko, Charmaine Smith, Tineke Fancourt, Leonid Churilov, Andrew Scott, Allison Barraclough, Joel Wight, Joe McKendrick, Wendi Lin, Fiona Swain, Eliza A. Hawkes, Colm Keane

Blood (2024) 144 (Supplement 1): 6213.

https://doi.org/10.1182/blood-2024-201230

Published: 2024

Journal Articles

Follicular Lymphoma Displays Distinct Gene Expression Profiles According to Histological Grade

Allison Barraclough, Eliza A. Hawkes, Denise Lee, James Nguyen, Patrick Hosking, Wendi Lin, Shivam Agrawal, Kimberly Wong, Geoffrey Chong, Enid Lam

Blood (2024) 144 (Supplement 1): 6203.

https://doi.org/10.1182/blood-2024-206571

Published: 2024

Journal Articles

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Blood (2024) 144 (Supplement 1): 567.

https://doi.org/10.1182/blood-2024-207439

Published: 2024

Journal Articles

Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language

Dawn Swan, Marsali Maclean, Niamh Waters, Denise Lee, Charmaine Smith, Arina Martynchyk, Eliza A. Hawkes, Jay Hocking

Blood (2024) 144 (Supplement 1): 5139.

https://doi.org/10.1182/blood-2024-193867

Published: 2024

Journal Articles

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Serif Sungur, Yao Yao, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Tasneem Rizvi, Eliza A. Hawkes, Zoe K McQuilten, Erica M. Wood, Nada Hamad, Tasman Armytage, Anna M. Johnston

Blood (2024) 144 (Supplement 1): 5126.

https://doi.org/10.1182/blood-2024-206277

Published: 2024

Journal Articles

Tribulations of trials in aggressive lymphoma

Allison Barraclough, Eliza A. Hawkes

Blood (2023) 142 (26): 2232–2234.

https://doi.org/10.1182/blood.2023022382

Published: 2023

Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Blood (2023) 142 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2023-181541

Published: 2023

Journal Articles

Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

Eliza A Hawkes, Rachel Fletcher, Andrew Wood, Stefanie Meyer, Simon Rule, Jingyang Zhang, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2023-174718

Published: 2023

Journal Articles

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

Geoff Chong, Jodie B Palmer, Allison A Barraclough, Leonid Churilov, Colm Keane, Sze Ting Lee, Denise Lee, Sumita Ratnasingam, Charmaine Smith, Eliza A Hawkes

Blood (2023) 142 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2023-173110

Published: 2023

Journal Articles

Infections in Lymphoma Patients Treated with Bispecific Therapies: A Systematic Review and Meta-Analysis

Gemma K Reynolds, Marsali Maclean, Benjamin Teh, Karin A Thursky, Monica A Slavin, Mary Ann Anderson, Eliza A Hawkes

Blood (2023) 142 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2023-185138

Published: 2023

Journal Articles

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Blood (2023) 142 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2023-173247

Published: 2023

NARROW

Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Toxicity Outcomes in Phase 1 Lymphoma Trials: Variable Reporting with High Use of Minimising Language in Published Abstracts at International Conferences

Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Displays Distinct Gene Expression Profiles According to Histological Grade

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Tribulations of trials in aggressive lymphoma

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

Infections in Lymphoma Patients Treated with Bispecific Therapies: A Systematic Review and Meta-Analysis

Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only